Search

Memorial Sloan Kettering's new chief nurse Tracy Gosselin says she was taken by surprise when she was asked to consider MSK's top nursing job.

… Thursday, May 5, 2022 Tracy Gosselin says she was taken by surprise when she got the call asking her to consider applying for the top nursing job at Memorial Sloan Kettering Cancer Center (MSK).  “I laughed and said, ‘I can give you lots of names,’ ” she recalls. After careful thought and consultation

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, February 29, 2024 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Yael David Awarded 2024 Alfred P. Sloan Research Fellowship Yael David Yael David, PhD ,  chemical biologist leading  The Yael David Lab  and   Associate Member of the  Chemical

MSK researchers are making important inroads in understanding and treating pancreatic cancer.

… Saturday, January 1, 2022 For Barbara Brigham, being diagnosed with pancreatic cancer in the fall of 2020 was a devastating blow in an already rough year. She had just lost her mother and husband after long illnesses, both needing extensive care. The 74-year-old semiretired librarian from Long Island

Targeting this signal with drugs might be one way to stop cancers from spreading.

… Thursday, July 26, 2018 Summary Scientists from the Sloan Kettering Institute have identified a key step in the process of metastasis, how cancer spreads to other parts of the body. The step is shared across tumor types and suggests a new angle for targeted therapy. In 90% of cancer deaths, what kills

MSK physicians and researchers design and conduct clinical trials that include adolescent and young adult (AYA) cancer patients, ensuring they are not lost between the typical siloes of adult and pediatric cancer trials.

… Monday, September 13, 2021 MSK physicians and researchers design and conduct clinical trials that include adolescent and young adult (AYA) cancer patients, ensuring they are not lost between the typical siloes of adult and pediatric cancer trials. As a result, more AYA patients benefit from an increasing

The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic mutation called a TRK fusion. Today’s decision marks a transformation in the field of precision medicine as this is the first time that an entirely new treatment has received a tumor-agnostic indication at its initial approval, meaning that the drug was approved based on mutation type rather than on where in the body the tumor originated.

… Monday, November 26, 2018 Bottom Line VIDEO | 02:42 Rihanna's Story of Treatment on a Clinical Trial with Larotrectinib Meet Rihanna, who was on a clinical trial with larotrectinib. Video Details The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic

Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials.

… Friday, September 21, 2018 Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials. The task force was announced in a statement from MSK President and

Learn how experimental vaccine might train the immune system to prevent pancreatic cancer from returning.

… Monday, June 10, 2024 Pancreatic cancer has long been a forbidding disease. While the five-year survival rate has inched upward in recent years, it remains quite low — about 12%. But surgeon-scientist Vinod Balachandran, MD , has focused on a glimmer of hope: A small percentage of people manage to beat

Discover what Memorial Sloan Kettering contributed to the science and medicine of x-rays.

… Tuesday, October 4, 2016 Summary Since 1902, Memorial Sloan Kettering has been a pioneer in the science and medicine of x-rays, developing many of the radiation techniques in use today. In a previous post , we recounted the history of radium therapy at Memorial Sloan Kettering. Radium, a naturally occurring

Investigators at Memorial Sloan Kettering Cancer Center, along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large-scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

… Monday, July 27, 2009 Investigators at Memorial Sloan Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the